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Abstract: The selection of a wound dressing is crucial for successful wound management. Conventional dressings are preferable for
the treatment of simple wounds. However, a bioactive wound dressing that supports wound management and accelerates the healing
process is required when it comes to treating non-self-healing wounds.
2-deoxy-D-ribose (2dDR) is a small deoxy sugar that naturally occurs in human body. Although we have previously demonstrated that
2dDR can be used to induce neovascularisation and accelerates wound healing in vitro and in vivo, the literature on small sugars is
conflicting, and the knowledge on how 2dDR achieves its biological activity is very limited.
In this study, several small sugars including D-glucose (DG), 2-deoxy-D-glucose (2dDG), 2deoxy-L-ribose (2dLR) were compared to
2dDR by investigating their effects on the metabolic activities of both human dermal microvascular endothelial cells (HDMECs) and
human dermal fibroblasts (HDFs). Then, for the first time, a two-dimensional (2D) scratch wound healing model was used to explore
the migratory response of HDFs in response to 2dDR treatment. Finally, 2dDR was incorporated into Poly(3-hydroxybutyrate-co3-hydroxyvalerate) (PHBV) polymer fibres via electrospinning, and the metabolic activity of both types of cells in vitro was investigated
in response to sugar release via Alamar Blue assay.
The results demonstrated that 2dDR was the only sugar, among others, that enhances the metabolic activity of both HDMECs and HDFs
and the migratory response of HDFs in a 2D scratch assay in a dose-dependent manner. In addition to direct administration, 2dDR was
also found to increase the metabolic activity of HDMECs and HDFs over 7 days when released from polymer fibres. It is concluded that
2dDR is a potential pro-angiogenic agent that has a positive impact not only on endothelial cells but also fibroblasts, which take a key
role in wound healing. It could easily be introduced into polymeric scaffolds to be released quickly to enhance the metabolic activity and
the migratory response of cells that are associated with angiogenesis and wound healing.
Key words: 2-deoxy-D-ribose (2dDR), deoxy-sugar, vascular endothelial growth factor (VEGF), angiogenesis, wound healing,
electrospinning

1. Introduction
Skin plays an important role in the prevention of the body
against microorganism invasion (Lee et al., 2006), from
dehydration, mechanical, chemical, and thermal damage,
and exposure to ultraviolet (UV) (Forslind et al., 1997;
Rees, 1999). Skin is composed of epidermal, dermal, and
subcutaneous layers (Honari, 2017), and wounding could
be superficial to include only the epidermal layer or deeper
and more complex, including dermal and subdermal layers
of the skin (Stroncek and Reichert, 2007).
Regular healing steps of a superficial wound includes
six main stages: (i) haemostasis, (ii) inflammation,
(iii) granular tissue formation, (iv) proliferation, (v)
neovascularisation, and (vi) remodelling (Kawasumi et al.,

2013). However, some of the wounds cannot go through
all these steps correctly due to several reasons, such as
depth and complexity of the wounds, repetitive trauma,
infection, comorbidity of the patients (Han and Ceilley,
2017). In the treatment of wounds, the selection of a
wound dressing is a critical factor that affects the healing
process. Conventional dressings such as gauze dressings,
plasters or bandages are cost-effective and useful for the
treatment of simple wounds, but they are only passive
dressings and do not improve the healing process. On
the other hand, modern dressings such as film, foam,
hydrogel, hydrocolloid, alginate dressings offer a chance to
enhance the healing of the wound rather than just to cover
it (Dhivya et al., 2015). These two types of dressings offer
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an opportunity to treat several types of wounds. However,
when it comes to treating non-self-healing chronic
wounds, more complex bioactive wound dressings are
required (Han and Ceilley, 2017).
The physiological tissue/wound healing process
is strictly controlled by cell-cell and cell-extracellular
matrix (ECM) interactions (Dikici, Aldemir Dikici, et al.,
2021). As a result of these interactions, growth factors are
released and play a key role in stimulating angiogenesis
and accelerating wound healing. Exogenous use of the
wound-related growth factors facilitates the healing
process (Badiu et al., 2011). The rationale behind the use
of growth factors is the improvement of the chemotactic
activity and proliferation of wound-related cells and
increasing angiogenesis in the wound area. Among
these, angiogenesis is crucial and takes a role not only
in the oxygen and nutrient transport and waste removal
during the very challenging proliferative phase but also
in the transmigration of immune cells to the wound area
during the inflammation phase. These critical tasks make
angiogenesis an indispensable step for the natural healing
process of wound healing (Tonnesen et al., 2000).
Platelet-derived growth factor (PDGF), fibroblast
growth factor (FGF), epidermal growth factor (EGF),
and vascular endothelial growth factor (VEGF) are
the commonly used growth factors either to induce
angiogenesis or to improve wound healing (Hunt et al.,
2000). Growth factors are considered the most effective
approach in promoting angiogenesis and accelerating
wound healing. However, the use of growth factors is
costly, and uncontrolled use of them is either ineffective
or not safe (Cheng et al., 1997; Grazul-Bilska et al., 2003).
VEGF has been shown to be the most effective growth
factor to induce angiogenesis (Hoeben et al., 2004), but it
has also been reported that the use of exogenous VEGF
in an uncontrolled manner may lead to the formation
of leaky, highly permeable and haemorrhagic blood
vessels, as observed in tumorigenesis (Cheng et al., 1997;
Yancopoulos et al., 2000; Cao et al., 2004). Other growth
factors that are frequently used for wound healing, EGF,
FGF, and PDGF, require either continuous and repeated
applications or a carrier system in order to provide
efficient healing. In addition, their high cost and safety
concerns limit the clinical accessibility of these agents
(Grazul-Bilska et al., 2003). Given both their high cost and
the risk of tumour formation, the safety of clinical use of
these pro-angiogenic agents exogenously is questionable,
and the need for alternative approaches to stimulate these
growth factors indirectly may offer a promising alternative
for the effective and safe stimulation of angiogenesis and
accelerate wound healing.
2-deoxy-D-ribose (2dDR) is a deoxy pentose sugar that
is found in the DNA’s nucleic acid structure in the human
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body. It is an endogenous metabolite and naturally formed
as a result of the degradation of thymidine to thymine by
thymidine phosphorylase (TP) (Figure 1) (Priestle and
Paris, 1996). The angiogenic potential of 2dDR was first
investigated in the early 90s (Finnis et al., 1993) and then
in the early 2000s (Sengupta et al., 2003). Both studies
hypothesised that 2dDR as the side product might be
the potential cause of the pro-angiogenic activity of the
TP (today also known as platelet-derived endothelial
cell growth factor (PD-ECGF)). Although these studies
suggested the positive impact of 2dDR on proliferation
and migration of endothelial cells, the biological and
molecular efficiency in angiogenesis and wound healing
processes has not been investigated in detail since then.
Recently, we reported that 2dDR achieves its activity
via stimulation of VEGF production by human aortic
endothelial cells (HAECs) in vitro (Dikici, Aldemir Dikici,
et al., 2019; Dikici, Bullock, et al., 2020) and in chick
chorioallantoic membrane (CAM) assay (Dikici, Mangir,
et al., 2019) in vivo. Furthermore, we demonstrated that
2dDR releasing alginate dressings is an effective treatment
for chronic wounds in a diabetic rat model (Andleeb et al.,
2020; Dikici, Yar, et al., 2021).
Alongside 2dDR, three other small sugars (2-deoxy-Lribose (2dLR), 2-deoxy-D-glucose (2dDG), and D-glucose
(DG)) were tested for their potential pro-angiogenic
activity. These sugars were selected initially due to being
involved in angiogenesis-related studies (either in a positive
or negative way) in the literature. However, the rationale
behind selecting (i) 2dLR was to investigate whether
this effect is structure-dependent or not as 2dLR is the
stereoisomer of 2dDR and to explore how conformational
change affects the biological activity of a sugar, (ii) DG
was to see if the effect is due to the metabolisation of sugar
and again if it is independent of the sugar-origin or not,
and (iii) 2dDG was to see what would happen if we use a
sugar which recapitulates the function of DG but cannot
undergo further glycolysis.
Wound dressings are made of both synthetic and
natural materials. Natural materials are advantageous
due to their superior biological activity in supporting the
adhesion and functionality of cells. However, all bioactive
components should be removed to avoid undesired host
response upon implantation (Mano et al., 2007; Guo and
Ma, 2014). On the other hand, synthetic materials are
attractive due to having high control on mechanical and
physical properties and no host response concerns due to
their nonbiological origin (Magnusson et al., 2011).
To date, various synthetic polymers have been
reported as biomaterials for their use in angiogenesis,
tissue engineering, and wound healing research. These
polymers include but not limited to polycaprolactone
(PCL) (Zhang et al., 2007; Pektok et al., 2008; Singh et al.,
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Figure 1. The degradation of thymidine to thymine by the enzymatic activity of TP. Following the degradation, 2dDR-1phosphate (2dDR1P) occurs, and the dephosphorylation of 2dDR1P forms 2dDR, which can pass the cell membrane.

2011), polylactic acid (Hegen et al., 2011; Jia et al., 2013),
poly(glycolic acid) (Hoerstrup et al., 2006), poly(lactic-coglycolic acid) (Iwai et al., 2004), polyurethane (Grasl et al.,
2010; Huang et al., 2011), polyglycerol sebacate (Motlagh
et al., 2006). Similar to synthetic polymers, naturallysourced polymers are also widely used in various studies.
The most popular ones are polyhydroxyalkanoates,
including Poly(3-hydroxybutyrate) (Akaraonye et al.,
2016), Poly(3‐hydroxyoctanoate) (Bagdadi et al., 2018),
Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV)
(Sultana and Khan, 2012; Ortega et al., 2015), and others
such as collagen (Berglund et al., 2004; Zhu et al., 2009,
2014), gelatin (Doi et al., 2007; Panzavolta et al., 2011),
alginate (Augst et al., 2006; Azam et al., 2019), elastin
(Engbers-Buijtenhuijs et al., 2006), silk fibroin (Lovett et
al., 2010; Marelli et al., 2012), dextran (Sun et al., 2011),
and hyaluronic acid (Zhu et al., 2014). Considering the
pros and cons of these natural polymers, PHBV appears
to have great potential as a biomaterial because of its
high biocompatibility and being safely biodegradable.
3-hydroxybutanoic acid naturally occurs in human body

and is a degradation product of PHBV. Its degradation
product being a natural metabolite accounts for its high
biocompatibility (Quillaguamán et al., 2010). In addition,
PHBV offers superior mechanical strength compared to
other natural polymers, and the ease of manufacturing
PHBV micro and nanofibres via electrospinning makes it
a good candidate for the production of fibrous bioactive
wound dressings to be used in wound management
(Dikici, Claeyssens, et al., 2020a).
Accordingly, in this study, the effect of different doses
of 2dDR on the metabolic activity of human dermal
microvascular endothelial cells (HDMECs) that has a
key role in wound healing (Tonnesen et al., 2000) was
evaluated compared to other small sugars in order to
clarify the conflicting literature on small sugars and the
specificity of the pro-angiogenic response to 2dDR. Then,
the stimulation of proliferation and migration behaviour
of human dermal fibroblasts (HDFs) in response to 2dDR
was investigated using a two-dimensional (2D) wound
healing (scratch) model. Following the dose-response and
2D wound healing studies, 2dDR was incorporated into
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PHBV nanofibres to be used as a bioactive wound dressing
and showed its release over 10 days. 2dDR-releasing PHBV
dressings were then evaluated for their performance
in improving the viability of two different types of cells,
HDFs and HDMECs, both of which actively take part in
the wound healing process in vivo.
2. Materials
A total of 37% formaldehyde solution, AlamarBlue cell
viability assay, amphotericin, penicillin/streptomycin,
dimethyl sulphoxide (DMSO), dichloromethane (DCM),
methanol, fetal bovine serum (FBS), vascular endothelial
growth factor (VEGF), epithelial growth factor (EGF),
phosphate-buffered saline (PBS), Poly3-hydroxybutyrateco-3-hydroxyvalerate (PHBV), and trypsin EDTA
were purchased from Sigma Aldrich. Human Dermal
Microvascular Endothelial Cells (HDMECs), Endothelial
Cell Growth Medium (EC GM) and EC GM Supplement
Pack were purchased from PromoCell. Human Dermal
Fibroblasts (HDFs) and Fibroblast Growth Medium
(FGM) BulletKit were purchased from Lonza.
3. Methods
3.1. Assessment of the metabolic activity of HDMECs in
response to small sugars (2dDR, 2dLR, 2dDG, DG) and
VEGF
A total of 10 mM stock solutions of 2dDR, 2dLR, 2dDG
and DG were prepared by dissolving the sugars in low
serum (2% FCS) EC GM and filtered using a 0.2 µm syringe
filter. The stock sugar solutions were then diluted 10× and
100× in sterile EC GM to prepare 1 mM and 100 µM sugar
solutions. 80 ng/mL VEGF solution was prepared in sterile
EC GM and used as a positive control. Low serum EC
GM was used as a control group in the metabolic activity
experiments.
HDMECs, between passages 2 and 6, were cultured
in EC GM supplemented with a total of 10% FBS and
growth medium 2 kit supplements at 37 °C and 5% CO2.
The growth medium was replaced every 3 days until they
reached ~80%–90% confluency.
AlamarBlue Cell Viability Assay was used to measure
the metabolic activity of HDMECs over 7 days in response
to 100 µM, 1 mM and 10 mM concentrations of 2dDR,
2dLR, 2dDG, and DG as described previously (Aldemir
Dikici, Sherborne, et al., 2019; Dikici, Claeyssens, et al.,
2019). Once HDMECs reached confluence, they were
collected, prepared into a cell suspension, and added into
48-well plates (seeding density is 1x104 cells/cm2) HDMECs
were then cultured with EC GM either supplemented
with 100 µM, 1 mM and 10 mM concentrations of 2dDR,
2dLR, 2dDG, DG, or VEGF or as non-supplemented
(control). AlamarBlue readings were taken on days 1, 4,
and 7 to track the metabolic activity changes in response
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to sugar treatments. Briefly, 0.1 mM AlamarBlue solution
was prepared in EC GM. The growth medium of cells was
removed, and the cells were washed with PBS once. Then,
1 mL of AlamarBlue solution was added to each well and
incubated at 37°C for 4 h. After the incubation, 200 µL of
the solution was transferred into a 96-well plate, and the
fluorescence readings were taken at 540 nm (excitation)
and 635 nm (emission).
3.2. The effect of 2dDR on the metabolic activity of human dermal fibroblasts (HDFs)
Following the evaluations of different small sugars’ effects
on metabolic activity change of HDMECs, further doses of
2dDR (1 µM, 100 µM, 1 mM, 10 mM) were assessed to see
the effect of it on increasing the metabolic activity of HDFs.
For this, HDFs, between passages 3 and 8, were cultured in
FGM supplemented with a total of 10% FBS and BulletKit
supplements at 37°C and 5% CO2. The growth medium
was replaced every 3 days until they reached ~80%–90%
confluency.
AlamarBlue Cell Viability Assay was used to measure
the metabolic activity of HDFs over 7 days in response to 1
µM, 100 µM, 1 mM, and 10 mM concentrations of 2dDR.
Once HDFs reached confluence, they were collected,
prepared into a cell suspension, and added into 48-well
plates (seeding density is 1x104 cells/cm2). HDFs were
cultured with FGM either supplemented with 1 µM, 100
µM, 1 mM, and 10 mM of 2dDR or non-supplemented
(control). AlamarBlue readings were taken on days 1, 4,
and 7 to track the metabolic activity changes in response
to sugar treatments as described in Section 3.1.
3.3. Evaluating the effect of 2dDR on HDFs using a 2D
scratch wound healing assay
Scratch wound healing assay (Liang et al., 2007) was
used to evaluate the migratory response of HDFs when
administered with 2dDR compared to positive control
EGF. The principle of this assay is the destruction of
confluent cell monolayer to generate an acellular region,
which is available to cells for migration and repair. For this,
HDFs were cultured as described above, trypsinised, and
seeded into 24-well plates with a seeding density of 2×104
cells/cm2. Once HDFs are confluent, a scratch wound was
created by scraping the cell monolayer in a straight line
using a 200 µL pipette tip. Caution was given to keep the
sizes and width of the wound areas similar to minimise
variations.
Following the scratch, well plates were gently washed
with PBS to remove detached cells. Then, the FGM
(with antibiotics and 5% FBS) was replenished either
supplemented with 2dDR (1 µM and 1 mM), EGF (50 ng/
mL) or as non-supplemented (control). The well-plates
were returned to a cell culture incubator and incubated at
37 °C, 5% CO2, for 60 h until a full closure was observed in
one of the groups.
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An inverted microscope (Olympus, Japan) was used to
take digital images of the wound area. The images were
taken at the beginning of the experiment and after 12, 48,
and 60 h. Adobe Photoshop CS6 software (ADOBE Systems
Inc., San Jose, California, USA) was used to convert the
raw image to a black and white image to facilitate image
processing. For this, wound areas were drawn manually by
the magic wand (quick selection) tool. The areas outside
the wound zone were coloured black, while the wound
zone was coloured with white. Black and white images
were then imported to ImageJ software (Wayne Rasband,
National Institutes of Health, USA). The white zones
corresponding to the wound area were quantified using the
histogram function of ImageJ software, where histograms
of each image were analysed, and the white areas in the
histograms were tabulated to Microsoft Excel software
to calculate the percentage of wound reduction for each
group. Normalised percentage wound closure rates were
determined as the percentage wound area reduction per
the time point that the image was acquired.
3.4. Manufacturing of the PHBV nanofibrous wound
dressings loaded with 2dDR
Electrospinning was used to fabricate 2dDR releasing
PHBV fibres as bioactive wound dressings (Dikici, Mangir,
et al., 2019; Dikici, Claeyssens, et al., 2020b). Briefly, 10%
(w/w) electrospinning solution was prepared by dissolving
PHBV in DCM:methanol (90:10 w/w) in a fume hood prior
to electrospinning. 100 mg and 250 mg of 2dDR per 1 g of
PHBV were added to the electrospinning solution prior to
electrospinning. 5 mL of the solutions were then loaded
into 10 mL syringes equipped with 0.6 mm blunt syringe
tips and placed in a syringe pump. The electrospinning
was performed at room temperature from a fixed collector
distance of 17 cm with a flow rate of 40 µL/min, and a
voltage of 17 kV until all the solution was exhausted.
The surface morphology of 2dDR releasing wound
dressings was investigated under a scanning electron
microscope (SEM) (FEI QUANTA 250 FEG, USA)
(Aldemir Dikici et al., 2020). Fibre diameter and pore
sizes were measured using ImageJ as described previously
(Aldemir Dikici, Dikici, et al., 2019; Dikici, Claeyssens, et
al., 2020a).
3.5. Assessment of 2dDR release from the PHBV fibres
A spectrophotometric method was used for the detection
of 2dDR, as described previously (Dikici, Mangir, et al.,
2019; Dikici, Bullock, et al., 2020 ). Briefly, 100 mg and
250 mg 2dDR loaded PHBV dressings were cut into pieces
so to fit into a 6-well plate, weighed before the release
experiments and incubated in 2 mL of PBS for 10 days.
The 2dDR release were measured fluorometrically using
a spectrophotometer (Shimadzu UV2550, Japan). The
readings were converted to a percentage release of 2dDR
from the dressings before reporting.

3.6. Evaluation of the in vitro biological performance of
2dDR releasing PHBV dressings
Following the fabrication of 2dDR releasing PHBV
dressings, they were cut into 10 mm diameter circles using
a biopsy punch and disinfected in 70% ethanol for 45 min.
Then, the dressings were washed in PBS for 1 h (PBS was
refreshed every 20 minutes for a total of three times) and
placed into 12-well plates for cell seeding.
HDMECs and HDFs were cultured as described in the
previous sections, and once they reached to confluence,
they were trypsinised and seeded onto 2dDR releasing
PHBV scaffolds with a seeding density of 4 x 104 cells/cm2.
Scaffolds were kept at 37 °C for 60 min to allow cells to
attach. Then, 4 mL of EC GM (for HDMECs) and FGM
(for HDFs) were added to each well. PHBV dressings were
kept in culture for 7 days by changing the culture medium
every 2-3 days.
The metabolic activity of HDMECs and HDFs seeded
onto 2dDR releasing PHBV fibres were tracked over 7
days using Alamar Blue Cell Viability Assay as described
in previous sections (Dikici, Claeyssens, et al., 2020a). The
metabolic activity measurements were taken on days 1, 4,
and 7 as described in Section 3.1.
2.7. Statistical analysis
Statistical analysis was performed using a statistical
analysis software (GraphPad Prism, California, USA).
The analysis was conducted either using one-way or twoway analysis of variance (ANOVA). Error bars indicate
standard deviations unless otherwise stated.
4. Results
4.1. 2dDR improves the metabolic activity of HDMECs
but no other small sugars, 2dLR, 2dDG, and DG
The results of the AlamarBlue assay demonstrated that
2dDR, 2dLR and DG did not cause any change in the
metabolic activity of HDMECs compared to controls at
any doses tested, while VEGF increased the metabolic
activity significantly. In contrast, 2dDG at 1 mM and 10
mM doses was found to decrease the cellular activity even
on day 1.
2dDR at 100 µM and 1 mM doses and VEGF at 80 ng/
mL (as the positive control) has been found effective in
terms of increasing the activity of HDMECs on days 4
and 7. In contrast to 100 µM and 1 mM doses, the highest
concentration (10 mM) of 2dDR was found to decrease the
activity significantly on days 4 and 7. A similar trend was
observed for 2dLR at 10 mM dose, whereas lower doses
(100 µM and 1 mM) were ineffective at any time points, and
no statistically meaningful change was observed compared
to controls. For 2dDG, the reductions in the metabolic
activity of HDMECs on day 4 and 7 were more dramatic
compared to 2dDR and 2dLR, including the mid-dose
(1 mM) alongside the highest dose of 10 mM. However,
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100 µM dose of 2dDG caused a significant reduction in
the activity only on day 7 but not on days 1 and 4 (no
significant change was observed compared to controls).
Throughout the metabolic activity measurements, DG did
not show any change in the metabolic activity of HDMECs
at any concentration on any days compared to controls.
The metabolic activity changes of HDMECs over 7 days
in response to 100 µM, 1 mM, and 10 mM doses of DG
(Figure 2A), 2dDR (Figure 2B), 2dLR (Figure 2C), and
2dDG (Figure 2D) treatments are given in Figure 2.
Take home messages from this sugar comparison
study were as follows: (i) 2dDR (at 100 µM and 1 mM)
was the only sugar that enhances the metabolic activity of
HDMECs significantly at the end of 7 days, (ii) 2dDR (at
10 mM, on days 4 and 7), 2dLR (at 10 mM, on days 4 and 7)
and 2dDG (at 100 µM, 1 mM and 10 mM, on days 1, 4 and
7) caused a dramatic decrease in the activity of HDMECs
due to probable dose-dependent toxicity. For 2dDG, this
may not be surprising be explained as 2dDG has previously
been demonstrated as a potential anti-angiogenic agent

(Merchan et al., 2010; Kovacs et al., 2016). However, future
studies to investigate the negative effect of 2dDR and 2dLR
at higher concentrations on cells may provide significant
knowledge on the safety and potential dose-dependent
anti-angiogenic activity of these sugars.
4.2. 2dDR increases the metabolic activity of HDFs over
7 days
The metabolic activity measurements of HDFs over 7 days
showed that similar to that observed on HDMECs, 2dDR
treatment at 100 µM and 1 mM doses also increased the
metabolic activity of HDFs by days 4 and 7, while there was
no statistically meaningful difference on day 1. Although
1 µM dose of 2dDR caused a slight increase by days 4 and
7, it was not statistically different compared to controls.
The light microscope images of HDFs at the end of day 7
and the results of the AlamarBlue metabolic activity assay
in response to 2dDR treatment over 7 days are given in
Figure 3.
One thing to note is that, similar to HDMECs, a
significant decrease was observed in the activity of HDFs

A

B

C

D

Figure 2. The metabolic activity changes of HDMECs in response to treatment of several small sugars. The results of the AlamarBlue
metabolic activity assay in response to 100 µM, 1 mM, 10 mM concentrations of (A) DG, (B) 2dDR, (C) 2dLR, and (D) 2dDG treatment
(***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, not significant (ns) p ≥ 0.05, n = 3 ± SD).
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Control

2dDR (1 µM)

2dDR (1 mM)

2dDR (10 mM)

2dDR (100 µM)

Figure 3. Light microscope images show the morphologies of HDFs at the end of day 7. Graph shows the results of the AlamarBlue
metabolic activity assay in response to 2dDR treatment over 7 days. (***p ≤ 0.001, **p ≤ 0.01, not significant (ns) p ≥ 0.05, n = 3 ± SD).
Scale bars represent 200 µm.

when treated with 10 mM 2dDR. However, it seems like
HDFs were more tolerable to the highest dose of 2dDR
as the rate of decrease was lower compared to that of
HDMECs. In addition, light microscope images also
revealed that there were still some HDFs attached to
the well plate in contrast to endothelial cells, which has
previously been reported to detach completely from the
well plate when treated with 10 mM of 2dDR (Dikici,
Aldemir Dikici, et al., 2019).
4.3. 2dDR enhances the migratory response of HDFs in
2D scratch wound healing assay
2D scratch assay is a convenient and inexpensive protocol
for the analysis of cell migration corresponding to wound
healing in vitro (Liang et al., 2007). When assessing
the cellular migration in a scratch model, analysis of
two parameters provides valuable information on the
migratory response: the wound closure percentage and
the normalised wound closure rate. The wound closure

percentage indicates the percentage repopulation of
the scraped area by the cells. The normalised wound
closure rate demonstrates how effective the active agent
to accelerate the closure of the scraped area compared to
controls (either negative or positive) (Abdel-Naby et al.,
2017; Da Silva et al., 2019).
Following the metabolic activity studies of HDFs, the
scratch wound healing assay also showed that 1 mM of
2dDR caused an increase in the migratory response of
HDFs in 60 h compared to controls (Figure 4A). Although
none of the groups, including the positive control (EGF),
showed a statistically meaningful increase in the wound
closure by 12 hours, EGF and 1 mM 2dDR treatment
significantly accelerated the wound healing by 48 h
compared to controls. Although a slight increase was
observed in the percentage of wound closure, 1 µM 2dDR
has not been found statistically different than controls
(Figure 4B).
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When ormalized wound closure rates were investigated,
only EGF and 1 mM 2dDR treatments have been found to
increase the closure rates by 12, 48, and 60 h but no other
groups. EGF treatment increased the wound closure rate
by approximately 1,3-fold at all time points (12, 48 and
60 hours). Similarly, 1 mM 2dDR treatment caused an
increase of 1.1-fold, 1.2‑fold and 1.1-fold by 12, 48, and
60 h, respectively, in the wound closure rates (Figure 4C).
The light microscope and the processed images (given
in the top right of each image) showing the migration of
HDFs corresponding to 2D scratch wound closure over 60
h, and the quantified graphs of percentage wound closure
and normalised wound closure rates are given in Figure 4.
4.4. The results of the fabrication of 2dDR releasing
PHBV wound dressings and the release of 2dDR from
the fibres over 10 days
SEM images of the 2dDR releasing PHBV dressings
are given in Figure 5A. The addition of both 2dDR
concentrations significantly increased the fibre diameters
of the electrospun PHBV dressing. The inclusion of 100 mg
and 250 mg of 2dDR in the PHBV electrospinning solution
resulted in an increase in the average fibre diameter
from 0.55 ± 0.16 µm (control) to 0.71 ± 0.19 µm and
0.86 ± 0.29 µm, respectively. In contrast to fibre diameters,
no statistically meaningful increase was observed in the
pore sizes when 2dDR was added. The average pore sizes
were calculated as 5.92 ± 3.07 µm, 6.79 ± 2.90 µm, and
7.60 ± 2.79 µm, respectively for PHBV, PHBV + 2dDR
(100 mg) and PHBV + 2dDR (250 mg). The average fibre
diameter and pore sizes were shown in Figure 5B and 5C,
respectively.
The releases of 2dDR from PHBV fibres was measured
over 10 days, as shown in Figure 5D. By 3 days, 2dDR
releases from the PHBV fibres were approximately 82.2%
and 90.6% of the total 2dDR present in the polymer
solution for 100 mg and 250 mg 2dDR loaded scaffolds,
respectively. Almost 90.5% and 95.8% of the total 2dDR
were released from the 100 mg and 250 mg 2dDR loaded
dressings, respectively, by 7 days. No statistical difference
was found between the released amounts of 2dDR from
the dressings over 10 days, and, considering the possible
negative effect of the higher doses of 2dDR on cells, such
as observed in metabolic activity studies, 100 mg 2dDR
loaded PHBV dressings were selected for further in vitro
study.
3.5. 2dDR releasing wound dressings improves the metabolic activity of HDMECs and HDFs in vitro
Alongside the direct addition of 2dDR to the growth
media, the 2dDR released from the PHBV dressings were
also found to increase the metabolic activity of HDMECs
and HDFs over 7 days (Figure 6).
By day 1, the metabolic activity of HDFs was higher
than that of HDMECs attached to plain PHBV dressing.
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Although there was no statistically meaningful difference,
the activity of HDMEC and HDFs went up by 1.6-fold and
1.1-fold, respectively, when seeded onto 2dDR releasing
PHBV dressings. On day 4, by the release of 2dDR from
the PHBV dressings, the metabolic activity of HDMECs
and HDFs were increased significantly by approximately
1.6-fold and 1.3-fold, respectively. By day 7, cell activity
went up by 1.5-fold and 1.8-fold for HDFs and HDMECs
seeded onto the 2dDR-releasing PHBV fibres, respectively.
4. Discussion
Acute wounds can follow the physiological healing steps
successfully and heal with an expected rate and within a
predicted time. However, chronic, deeper and complex
wounds where usually more than one layer of skin is
damaged, and a constant infection occurs due to delayed
healing requires special attention and a bioactive approach
for successful healing.
Physiological wound healing is a complicated process
where cell-cell, cell-ECM interactions and growth factors
play key roles. The main steps of wound healing are
haemostasis, inflammation, granular tissue formation,
proliferation, neovascularization, and remodelling
(Figure 7) (Kawasumi et al., 2013). Ensuring a rapid
and successful vascularisation in the wound healing
are is vital particularly in the management of complex
and chronic wounds that fail to follow the physiological
healing steps without further assistance (Honnegowda et
al., 2015). Neovascularisation is an indispensable step of
the wound healing, and it plays a pivotal role not only in
the proliferative phase by supplying oxygen and nutrients
and by removing the waste and debris but also in the
transmigration of immune cells to the wound area during
the inflammation phase (Tonnesen et al., 2000).
The use of growth factors is a well-established and
effective way of developing active wound patches to
induce angiogenesis and accelerate wound healing.
Among many growth factors, VEGF is considered the
most effective stimulator of angiogenesis (Hoeben et
al., 2004). However, it has also been shown to stimulate
extremely leaky (Yancopoulos et al., 2000), too permeable
(Cao et al., 2004), and haemorrhagic (Cheng et al., 1997)
vessels that correspond to tumour angiogenesis (Oka et
al., 2007). Other growth factors such as EGF, FGF, and
PDGF are frequently used to accelerate wound healing
( Badiu et al., 2011; Servold, 1991). However, most of
the growth factors are too expensive to be used with
traditional wound dressing manufacturing methods. They
are also not very stable, require highly sensitive carrier
systems due to narrow effective dose ranges, and possess
safety concerns that limit the clinical accessibility of these
agents (Grazul-Bilska et al., 2003). Given both their high
cost and the risk of tumour formation, the safety of clinical
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Figure 4. (A) The inverted light microscope and the processed images (top right of each image) showing the migratory response
(corresponding to 2D wound closure over 60 hours) of HDFs when treated with two doses of 2dDR and EGF (positive control) compared
to controls. Images from the same wound area were taken at 0, 12, 48, and 60 h after the wound is created. Scale bars represent 200 µm.
The graphs show (B) the wound closure (%) and (C) normalised wound closure rate (%) of HDFs in response to 2dDR treatment. (***p
≤ 0.001, **p ≤ 0.01 *p ≤ 0.05, not significant (ns) p ≥ 0.05, n = 3 ± SD).
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PHBV + 2dDR (250 mg)

D

Figure 5. (A) The SEM images, (B) average fibre diameter, (C) average pore sizes of the PHBV electrospun wound dressings. (D) The
graph shows the release behaviour of 2dDR over 10 days from the PHBV fibres. (***p ≤ 0.001, *p ≤ 0.05, not significant (ns) p ≥ 0.05,
n = 3 ± SD).

Figure 6. The metabolic activity of HDFs and HDMECs
growing on the 2dDR releasing PHBV dressings over 7 days.
(***p ≤ 0.001, *p ≤ 0.05, not significant (ns) p ≥ 0.05, n = 3
± SD).

use of pro-angiogenic agents is questionable, and the need
for the investigation of alternative factors to stimulate
angiogenesis and accelerate wound healing is clear.
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2dDR is a small deoxy pentose sugar that is naturally
found in the human body in the nucleic acid structure.
During the dynamic metabolic processes of the DNA,
2dDR is formed by the TP activity as a side product of the
enzymatic degradation of thymidine into thymine (Priestle
and Paris, 1996). Starting from the early 90s (Finnis et al.,
1993; Sengupta et al., 2003), 2dDR has gained attention
as the main cause of the pro-angiogenic activity of TP.
However, none of these studies has investigated the details
of the 2dDR’s pro-angiogenic potential and wound healing
accelerating properties. After almost 23 years, we have
recently started to investigate 2dDR as a potential proangiogenic and wound healing agent and conducted doseresponse studies in vitro (Dikici, Aldemir Dikici, et al.,
2019) and in vivo (Dikici, Mangir, et al., 2019). In addition,
we investigated its potential to accelerate the healing of
chronic wounds using a diabetic rat wound healing model
(Andleeb et al., 2020) and showed that its pro-angiogenic
activity is via upregulating the production of VEGF by
HAECs (Dikici, Bullock, et al., 2020). Although we have
shown the biological efficiency of 2dDR on angiogenesis
and wound healing at the organism level, the investigation
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Figure 7. Schematic illustration of wound healing process. Six main phases of wound healing (bleeding, haemostasis, inflammation,
granular tissue formation, reepithelialisation, neovascularisation, and remodeling) were explained considering changes in cellular
densities and activities, extracellular matrix structure and density, and neovascularisation in the wound area.

of these properties at the cellular level using the cell
types associated with wound healing still possess critical
importance to reveal the details of the 2dDR’s activity. The
main role of HDFs in angiogenesis and wound healing is
to produce significant amounts of ECM molecules (Bishop
et al., 1999; Sorrell et al., 2007) and growth factors (Black
et al., 1998; Hudon et al., 2003). Thus, the importance
of the exploration of how HDFs would react to 2dDR
treatment is clear to be able to fully understand the 2dDR’s
biological importance. However, to date, no study has been
conducted to investigate the effect of 2dDR on fibroblasts’
proliferative and migratory responses.
Accordingly, in this study, three potential doses of
2dDR were compared with other small sugars, 2dLR,
2dDG, and DG to investigate its specificity to HDMECs,
a small-diameter blood vessel endothelial cells sourced
from human skin, which is a great representative cell type
that can be used in vitro angiogenesis and wound healing

studies (Oberringer et al., 2007). Then, the effect of 2dDR
treatment on HDFs’ proliferative and migratory response
was explored. Finally, 2dDR was loaded into PHBV fibres
to investigate its potential to be used as a bioactive wound
dressing.
2dLR, 2dDG, and DG sugars were selected not only due
to being involved in angiogenesis studies in literature but
also in an attempt to simply clarify whether the biological
activity of 2dDR is structure dependent or is it due to the
metabolism of any sugar by the cells. This allowed us to
partly investigate the specificity of 2dDR as a potential
pro-angiogenic agent to wound healing related cells. Our
current knowledge on small sugars and how they are
involved in angiogenesis pathways is quite conflicting. For
instance, 2dLR has previously been reported as a promoter
(Sengupta et al., 2003) and inhibitor (Uchimiya et al.,
2002) of angiogenesis almost in the same years. Similarly,
DG has been demonstrated as a potential agent to induce
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(Shigematsu et al., 1999) and reduce (Teixeira and
Andrade, 1999) angiogenesis. 2dDR has previously been
reported to induce apoptosis of normal human fibroblasts
when used at very high concentrations (Kletsas et al.,
1998) but in contrast, we have reported its positive impact
on endothelial cells (Dikici, Aldemir Dikici, et al., 2019;
Dikici, Bullock, et al., 2020) and HDFs (this study) when
used at 100 µM to 1 mM concentrations. These examples
clearly state the great importance of further exploration of
dose studies of these small sugars on cell types associated
with wound healing to reveal their potential therapeutic
use in wound management. In this context, it is aimed to
clarify these small sugars’ angiogenic and anti-angiogenic
activities in a dose-dependent manner. Our results showed
that 2dDR was the only one to increase the metabolic
activity of HDMECs among all the small sugars used
in this study. Treatment of 100 µM and 1 mM 2dDR
significantly increased the cellular activity over 7 days.
One probable explanation is the upregulation of VEGF
in response to the 2dDR treatment of the cells (Dikici,
Bullock, et al., 2020). At the higher doses (10 mM), 2dDR
caused the detachment of HDMECs from the well plate
such as previously observed for HAECs (Dikici, Aldemir
Dikici, et al., 2019). 2dDR has also been found effective
to increase fibroblast activity when administered at similar
doses. 100 µM and 1 mM doses also increased the activity
of HDFs, where 1 µM was not effective. One thing to
note was that the highest concentration (10 mM) caused
the death of HDFs, but less detachment of HDFs was
observed compared to HDMECs. This is not surprising
as HDMECs are quite sensitive to culture conditions than
HDFs (Dikici, Claeyssens, et al., 2020b). This cytotoxic
effect of 2dDR at 10 mM is likely to be due to the dosedependent effect of 2dDR, which has previously been
reported to induce apoptosis of normal human fibroblasts
when used at high concentrations (10 mM to 50 mM)
(Kletsas et al., 1998). The results of the 2D scratch wound
healing assay demonstrated that 2dDR was increasing the
migratory response of HDFs with an increased wound
closure rate. One mM concentration of 2dDR has been
found approximately 88% and 84% effective at 48 h and
60 h, respectively, in wound closure rate compared to EGF,
positive control. At the end of 60 h, no wound closure was
observed in the control groups.
2dDR is highly soluble in water and organic solvents,
which makes it easy to incorporate into polymeric fibres.
The addition of 2dDR into the PHBV solution did not alter
the microstructure of the electrospun fibres. A smooth
and beadless morphology was obtained from all PHBV
electrospinning groups. Both 2dDR concentrations slightly
increased the average fibre diameter of the scaffolds but
did not change the average pore size. Although studying
the release kinetics of 2dDR would extend our knowledge
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on what would be an ideal release behaviour for the
acceleration of wound healing and how does the release
of 2dDR from PHBV fibres fits this profile, exploration
of the release kinetics of 2dDR was beyond the merits
of this study. Thus, the main objective of this work was
kept as simple as possible to investigate whether 2dDR
can be loaded into PHBV fibres and released from them
in a certain period of time to show the biological activity.
The release behaviour of 2dDR from the PHBV fibres
was observed over 10 days from both concentrations.
More than 90% of the 2dDR was released just in 7 days.
We have previously observed a similar release behaviour
from a variety of biomaterials ( Azam et al., 2019; Dikici,
Mangir, et al., 2019; Andleeb et al., 2020), which has been
found to stimulate angiogenesis and accelerate wound
healing, respectively. Similarly, in this study, we observed
a significant increase in the metabolic activity of two cell
types that take key roles in wound healing, HDMECs and
HDFs, when cultured on 2dDR releasing PHBV dressings
over 7 days compared to controls. By day 7, The release
of 2dDR from PHBV dressings increased the metabolic
activity of HDFs and HDMECs significantly by 1.5-fold
and 1.8-fold, respectively.
To date, no studies have been conducted to investigate
the effect of 2dDR on the migratory and proliferative
response of fibroblast cells, which take important roles
in physiological wound healing process (Desjardins-Park
et al., 2018). This study makes a unique contribution to
the field of angiogenesis and wound healing by exploring
the stimulatory role of 2dDR on fibroblasts, for the first
time, alongside endothelial cells. Furthermore, the data
presented in this paper will contribute significantly to the
translation of 2dDR incorporated wound management
products into the clinic. Although our current knowledge
(including the conclusions from this study) on 2dDR
demonstrates its high potential to be used to promote
angiogenesis and accelerate wound healing in vitro and
in vivo, it is important to note that further investigation
of the inhibitory effect of 2dDR when given at higher
concentrations may prove significant information on
the safety and potential dose-dependent anti-angiogenic
activity prior to the clinical translation of this small sugar.
Finally, the metabolism of 2dDR by bacteria localised
either surrounding or within the wound is needed to
be investigated to reveal whether 2dDR might lead to
overgrowth of pathogenic species and consecutively
wound infection.
5. Conclusion
To conclude, among the small sugars investigated in the
scope of this study, 2dDR was the only small sugar that
increases the metabolic activity of HDMECs and HDFs
when used as a supplement in the growth medium. In
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addition, 2dDR has also been shown, for the first time, to
stimulate the migratory response of HDFs in a 2D wound
healing assay when used at 1 mM concentration. It has been
found approximately 85% effective in terms of accelerating
the wound closure rate compared to EGF, positive control.
Alongside the direct addition to the growth medium,
2dDR was also effective in increasing the metabolic
activity of both cell types when released from PHBV fibres
over 7 days. The release of 2dDR improved the metabolic
activity of HDFs and HDMECs growing on polymer fibres
by 7 days. This study demonstrates that the introduction
of 2dDR into the biomaterials offers a promising approach

that can be used to enhance not only the metabolic activity
of endothelial cells but also the metabolic activity and the
migratory response of fibroblasts, which play a key role in
wound healing.
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